{"nctId":"NCT05219968","briefTitle":"Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults","startDateStruct":{"date":"2022-01-27","type":"ACTUAL"},"conditions":["Chronic Sinusitis","Chronic Rhinosinusitis (Diagnosis)"],"count":196,"armGroups":[{"label":"LYR-210","type":"EXPERIMENTAL","interventionNames":["Drug: LYR-210","Other: Background Therapy"]},{"label":"Sham procedure control","type":"SHAM_COMPARATOR","interventionNames":["Drug: Sham procedure control","Other: Background Therapy"]}],"interventions":[{"name":"LYR-210","otherNames":[]},{"name":"Sham procedure control","otherNames":[]},{"name":"Background Therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age â‰¥18\n* Diagnosed as having CRS\n* Undergone at least 2 trials of medical treatments in the past\n* Mean 3 cardinal symptom (3CS) score\n* Bilateral ethmoid disease confirmed on CT\n* Has been informed of the nature of the study and provided written informed consent\n* Agrees to comply with all study requirements\n* If on a waiting list for sinonasal surgery, willing to be removed from list or have surgery date cancelled for the duration of the study.\n\nExclusion Criteria:\n\n* Inability to tolerate topical anesthesia or endoscopic procedure\n* Previous nasal surgery\n* Presence of nasal polyp grade 2 or higher\n* Seasonal allergic rhinitis\n* Perennial rhinitis with symptoms that are well controlled by regular use of intranasal corticosteroids\n* Severe asthma\n* History or clinical evidence or suspicion of invasive fungal sinusitis, allergic fungal rhinosinusitis, atrophic rhinitis, or odontogenic sinusitis\n* Obstruction preventing proper placement and retention of LYR-210 as seen on endoscopy\n* Anatomic variation that, in the opinion of the investigator, would adversely impact placement of LYR-210 as seen on CT\n* Known history of hypersensitivity or intolerance to corticosteroids\n* Known history of hypothalamic pituitary adrenal axial dysfunction\n* Previous pituitary or adrenal surgery\n* Dental procedure/implant on maxillary dentition within 4 weeks of the Screening visit.\n* Past or present acute or chronic intracranial or orbital complications of CRS\n* History or diagnosis (in either eye) of glaucoma or ocular hypertension\n* Past or present functional vision in only 1 eye\n* Past, present, or planned organ transplant or chemotherapy with immunosuppression\n* Currently positive for COVID-19 or residual sinonasal symptoms from a previous COVID-19 infection\n* Pregnant or breast feeding. Females of child-bearing potential must test negative for pregnancy at the time of screening\n* Evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments\n* Currently participating in an investigational drug or device study\n* Determined by the investigator as not suitable to be enrolled","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps.","description":"The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. The diary is completed daily by study participants throughout the study. Each symptom/each question is rated on a 4-point (0-3) scale where 0= none/absent symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms. The composite score of 3CS is the sum of the three cardinal symptom scores.\n\nThe 3CS total score ranges from 0-9, with higher scores indicating worse symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.13","spread":"2.172"},{"groupId":"OG001","value":"-2.06","spread":"2.136"}]}]}]},{"type":"SECONDARY","title":"CFBL in the 7-day Average Composite Score of 3CS in All Participants at Week 24.","description":"The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. The diary is completed daily by study participants throughout the study. Each symptom/each question is rated on a 4-point (0-3) scale where 0= none/absent symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms. The composite score of 3CS is the sum of the three cardinal symptom scores.\n\nThe 3CS total score ranges from 0-9, with higher scores indicating worse symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.35","spread":"2.278"},{"groupId":"OG001","value":"-1.83","spread":"2.104"}]}]}]},{"type":"SECONDARY","title":"CFBL in the 22-item Sino-Nasal Outcome Test (SNOT-22) Total Score at Week 24","description":"The SNOT-22 questionnaire is a 22-item disease-specific quality of life instrument. Each symptom is scored on a 6-point scale where 0 = no problem and 5 = problem as bad as it can be. The total SNOT-22 score is the sum of the 22 items and can range from 0 to 110 with higher scores indicating worse symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.7","spread":"21.67"},{"groupId":"OG001","value":"-15.7","spread":"18.55"}]}]}]},{"type":"SECONDARY","title":"CFBL in the 3-D Volumetric CT Score at Week 20","description":"The percent opacification of the bilateral anterior and posterior ethmoids will be assessed by 3-D volumetric CT analysis at baseline and Week 20.\n\nA negative change from Baseline indicates improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.705","spread":"10.9320"},{"groupId":"OG001","value":"-0.279","spread":"9.9706"}]}]}]},{"type":"SECONDARY","title":"Participants With Rescue Treatments for CRS Through Week 24","description":"This endpoint is descriptively summarized per the prespecified plan. This includes participants that used systemic corticosteroid for any reason as well as participants that were recommended/underwent sinonasal surgery.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":124},"commonTop":["Epistaxis","Nasal Odour","Chronis Sinusitis","Sinusitis","Upper Respiratory Tract Infection"]}}}